Cargando…

Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)

BACKGROUND: Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to further invasive and/or expensive investigations. Little is known of the consequences in people with an initial abnormal liver function (ALF) test in primary care and with no obvious liver d...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnan, Peter T, McLernon, David, Steinke, Douglas, Ryder, Stephen, Roderick, Paul, Sullivan, Frank M, Rosenberg, William, Dillon, John F
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868021/
https://www.ncbi.nlm.nih.gov/pubmed/17437630
http://dx.doi.org/10.1186/1472-6963-7-54
_version_ 1782133369566396416
author Donnan, Peter T
McLernon, David
Steinke, Douglas
Ryder, Stephen
Roderick, Paul
Sullivan, Frank M
Rosenberg, William
Dillon, John F
author_facet Donnan, Peter T
McLernon, David
Steinke, Douglas
Ryder, Stephen
Roderick, Paul
Sullivan, Frank M
Rosenberg, William
Dillon, John F
author_sort Donnan, Peter T
collection PubMed
description BACKGROUND: Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to further invasive and/or expensive investigations. Little is known of the consequences in people with an initial abnormal liver function (ALF) test in primary care and with no obvious liver disease. Further investigations may be dangerous for the patient and expensive for Health Services. The aims of this study are to determine the natural history of abnormalities in LFTs before overt liver disease presents in the population and identify those who require minimal further investigations with the potential for reduction in NHS costs. METHODS/DESIGN: A population-based retrospective cohort study will follow up all those who have had an incident liver function test (LFT) in primary care to subsequent liver disease or mortality over a period of 15 years (approx. 2.3 million tests in 99,000 people). The study is set in Primary Care in the region of Tayside, Scotland (pop approx. 429,000) between 1989 and 2003. The target population consists of patients with no recorded clinical signs or symptoms of liver disease and registered with a GP. The health technologies being assessed are LFTs, viral and auto-antibody tests, ultrasound, CT, MRI and liver biopsy. The study will utilise the Epidemiology of Liver Disease In Tayside (ELDIT) database to determine the outcomes of liver disease. These are based on hospital admission data (Scottish Morbidity Record 1), dispensed medication records, death certificates, and examination of medical records from Tayside hospitals. A sample of patients (n = 150) with recent initial ALF tests or invitation to biopsy will complete questionnaires to obtain quality of life data and anxiety measures. Cost-effectiveness and cost utility Markov model analyses will be performed from health service and patient perspectives using standard NHS costs. The findings will also be used to develop a computerised clinical decision support tool. DISCUSSION: The results of this study will be widely disseminated to primary care, as well as G.I. hospital specialists through publications and presentations at local and national meetings and the project website. This will facilitate optimal decision-making both for the benefit of the patient and the National Health Service.
format Text
id pubmed-1868021
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18680212007-05-12 Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE) Donnan, Peter T McLernon, David Steinke, Douglas Ryder, Stephen Roderick, Paul Sullivan, Frank M Rosenberg, William Dillon, John F BMC Health Serv Res Study Protocol BACKGROUND: Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to further invasive and/or expensive investigations. Little is known of the consequences in people with an initial abnormal liver function (ALF) test in primary care and with no obvious liver disease. Further investigations may be dangerous for the patient and expensive for Health Services. The aims of this study are to determine the natural history of abnormalities in LFTs before overt liver disease presents in the population and identify those who require minimal further investigations with the potential for reduction in NHS costs. METHODS/DESIGN: A population-based retrospective cohort study will follow up all those who have had an incident liver function test (LFT) in primary care to subsequent liver disease or mortality over a period of 15 years (approx. 2.3 million tests in 99,000 people). The study is set in Primary Care in the region of Tayside, Scotland (pop approx. 429,000) between 1989 and 2003. The target population consists of patients with no recorded clinical signs or symptoms of liver disease and registered with a GP. The health technologies being assessed are LFTs, viral and auto-antibody tests, ultrasound, CT, MRI and liver biopsy. The study will utilise the Epidemiology of Liver Disease In Tayside (ELDIT) database to determine the outcomes of liver disease. These are based on hospital admission data (Scottish Morbidity Record 1), dispensed medication records, death certificates, and examination of medical records from Tayside hospitals. A sample of patients (n = 150) with recent initial ALF tests or invitation to biopsy will complete questionnaires to obtain quality of life data and anxiety measures. Cost-effectiveness and cost utility Markov model analyses will be performed from health service and patient perspectives using standard NHS costs. The findings will also be used to develop a computerised clinical decision support tool. DISCUSSION: The results of this study will be widely disseminated to primary care, as well as G.I. hospital specialists through publications and presentations at local and national meetings and the project website. This will facilitate optimal decision-making both for the benefit of the patient and the National Health Service. BioMed Central 2007-04-16 /pmc/articles/PMC1868021/ /pubmed/17437630 http://dx.doi.org/10.1186/1472-6963-7-54 Text en Copyright © 2007 Donnan et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Donnan, Peter T
McLernon, David
Steinke, Douglas
Ryder, Stephen
Roderick, Paul
Sullivan, Frank M
Rosenberg, William
Dillon, John F
Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title_full Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title_fullStr Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title_full_unstemmed Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title_short Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE)
title_sort development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [hta03/38/02]. abnormal liver function investigations evaluation (alfie)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868021/
https://www.ncbi.nlm.nih.gov/pubmed/17437630
http://dx.doi.org/10.1186/1472-6963-7-54
work_keys_str_mv AT donnanpetert developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT mclernondavid developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT steinkedouglas developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT ryderstephen developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT roderickpaul developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT sullivanfrankm developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT rosenbergwilliam developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie
AT dillonjohnf developmentofadecisionsupporttooltofacilitateprimarycaremanagementofpatientswithabnormalliverfunctiontestswithoutclinicallyapparentliverdiseasehta033802abnormalliverfunctioninvestigationsevaluationalfie